Any current/future new fundraising through debt or equity?

No significant capital expenditure (capex) or expansion planned for the next one year, indicating no major immediate need for fundraising. The company plans only small capex related to environmental initiatives (e.g., multi-effect evaporation operator). Current focus is on consolidating and filling existing capacity rather than building new capacity. Long-term debt is INR 170 crores and short-term debt is INR 90 crores, with an average borrowing cost below 8%. No explicit mention of any ongoing or planned fundraising through debt or equity in the call transcript. Emphasis is on growi

Any current/future capex/capital investment/strategic investment?

No significant capex planned for the next one year as the company aims to consolidate its existing capacities. Small capex planned is related to environmental upgrades, such as installing multi-effect evaporators (ME) and other environmental compliance equipment. Focus is on utilizing existing capacity (about 2,000 KL at Vizag plant for Ibuprofen) by filling it with more products rather than expanding physical capacity. Strategic focus is on product mix expansion, backward integration, and entering new markets rather than capital investment in new facilities. No new building blocks or capacity

Future growth expectations in sales/revenue/volumes?

FY '23 revenue growth target is around 10%; FY '24 projected growth is 15% to 20%. Volume growth is expected to be strong, with sequential and year-over-year volume growth seen; e.g., 30%-35% volume growth reported despite price corrections. Focus on ramping up ibuprofen capacity to reach INR 600-700 crores topline, becoming one of the largest manufacturers. Efforts to fill existing large capacity (e.g., 2,000 KL in Vizag plant) with high volume products and some niche products. New product launches and geographic expansion planned; anti-diabetic segment expected to contribute around 2

Future growth expectations in earnings/operating earnings/profits/EPS?

SMS Pharmaceuticals targets top-line growth of 15% to 20% for FY '24, driven mainly by increased volumes, especially in Ibuprofen and anti-diabetic products. Gross margins are expected to stabilize around 30%-35% over the next 2-3 years, excluding any extraordinary events. EBITDA margins are anticipated to improve, with a recovery to 15%-18% starting Q4 FY '23 and continuing growth in FY '24. Operating leverage from higher capacity utilization and cost reductions through backward integration will aid margin expansion. The company is reducing reliance on ARV products (now ~8% of revenue) and fo

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention specific details about the current or expected order book or pending orders. However, the management discussed increasing volumes, particularly in ibuprofen, with current capacity utilization around 50% at Vizag plant (150 tons per month of 300-ton capacity). There is mention of ARV segment orders being tender-based, with demand depending on winning tenders; the company acts as a contract manufacturer (CMO) in this space. Inventory management and destocking are ongoing, expected to move out over next 2-3 quarters. The focus is on filling existing capa

SMS Pharmaceuticals LtdQ2 FY23Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹479P/E: 43.4Market Cap: ₹4.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

FY '23 revenue growth target is around 10%; FY '24 projected growth is 15% to 20%.
Volume growth is expected to be strong, with sequential and year-over-year volume growth seen; e.g., 30%-35% volume growth reported despite price corrections.
Focus on ramping up ibuprofen capacity to reach INR 600-700 crores topline, becoming one of the largest manufacturers.
Efforts to fill existing large capacity (e.g., 2,000 KL in Vizag plant) with high volume products and some niche products.
New product launches and geographic expansion planned; anti-diabetic segment expected to contribute around 25%-30% of topline in future.
Growth driven by higher volumes, operating leverage, and process improvements to improve margins alongside revenue increase.
Inventory destocking expected to gradually ease over 2-3 quarters, aiding smoother sales growth.

Margin guidance

Category 3

SMS Pharmaceuticals targets top-line growth of 15% to 20% for FY '24, driven mainly by increased volumes, especially in Ibuprofen and anti-diabetic products.
Gross margins are expected to stabilize around 30%-35% over the next 2-3 years, excluding any extraordinary events.
EBITDA margins are anticipated to improve, with a recovery to 15%-18% starting Q4 FY '23 and continuing growth in FY '24.
Operating leverage from higher capacity utilization and cost reductions through backward integration will aid margin expansion.
The company is reducing reliance on ARV products (now ~8% of revenue) and focusing on non-ARV products with stable, sustainable margins.
Inventory destocking will take 2-3 quarters, with expected gradual improvement in cost structures (below gross margin costs expected to rise only 10%-15% over two years).
No major capex planned; focus remains on consolidating and optimizing existing capacity for profitability growth.

See what SMS Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No significant capital expenditure (capex) or expansion planned for the next one year, indicating no major immediate need for fundraising.
The company plans only small capex related to environmental initiatives (e.g., multi-effect evaporation operator).
Current focus is on consolidating and filling existing capacity rather than building new capacity.
Long-term debt is INR 170 crores and short-term debt is INR 90 crores, with an average borrowing cost below 8%.
No explicit mention of any ongoing or planned fundraising through debt or equity in the call transcript.
Emphasis is on growing revenue via existing capacities and product mix rather than through additional funding.

Order book

The transcript does not explicitly mention specific details about the current or expected order book or pending orders.
However, the management discussed increasing volumes, particularly in ibuprofen, with current capacity utilization around 50% at Vizag plant (150 tons per month of 300-ton capacity).
There is mention of ARV segment orders being tender-based, with demand depending on winning tenders; the company acts as a contract manufacturer (CMO) in this space.
Inventory management and destocking are ongoing, expected to move out over next 2-3 quarters.
The focus is on filling existing capacity with high-volume products and adding new products to the pipeline rather than expanding capacity.
No direct quantification of pending orders or exact order book value is provided in the call transcript.

See what SMS Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

No significant capex planned for the next one year as the company aims to consolidate its existing capacities.
Small capex planned is related to environmental upgrades, such as installing multi-effect evaporators (ME) and other environmental compliance equipment.
Focus is on utilizing existing capacity (about 2,000 KL at Vizag plant for Ibuprofen) by filling it with more products rather than expanding physical capacity.
Strategic focus is on product mix expansion, backward integration, and entering new markets rather than capital investment in new facilities.
No new building blocks or capacity additions are planned currently.

Track SMS Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSMS Pharmaceuticals Ltd

Rev 3Mar 3

See where SMS Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

SMS Pharmaceuticals Ltd Q2 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season